Park Square has placed Per Greisen Jr., Ph.D., as Vice President of Computational Drug Design at BioMap. BioMap has an end-to-end drug discovery engine, which is powered by a collective range of high-dimensional human disease data, high-throughput biology, a cutting-edge AI engine, and a high-performance biological computing platform.

Greisen most recently served as Director, Computational Drug Discovery at Novo Nordisk. He held this role from 2020-2023. From 2019-2020, Greisen was Director, Computational Biology at enEvolv, a developer of micro-organisms that produce chemicals, enzymes, and small molecules. During his tenure, he used machine learning with protein and DNA data to design and develop biosensors. He joined Novo Nordisk as a Specialist in 2015 and served as a Principal Modelling Scientist beginning in 2019. In these roles he worked to design proteins and novel protein binders for small molecules. He began his career in 2012 as a Senior Postdoctoral Fellow at the University of Washington in David Baker’s lab. While there, he researched computational protein modeling and design with Rosetta.

Greisen received his B.S. in Biochemistry from the University of Copenhagen, his M.S. in Bioinformatics from the University of Copenhagen, and his Ph.D. in Physics from the Technical University of Denmark.